Macrophage‐derived CD38 mediates colitis through NAD + depletion
The Journal of Physiology · 2026
DOI: 10.1113/jp291548 ↗At a glance
Journal article in The Journal of Physiology, 2026. Written by Yanni Wu and 11 co-authors. Institution: Animal Nutrition Institute, Sichuan Agricultural University, Chengdu, China. Major MEDLINE topics: NAD, ADP-ribosyl Cyclase 1, Colitis, Macrophages. 44 references. Funded by: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (original language)
Colitis, a chronic inflammatory bowel disease (IBD), is pathologically linked to immune dysregulation; however, the contribution of cellular metabolic alterations to its pathogenesis remains incompletely understood. In this study, untargeted metabolomic analysis revealed marked disruption of NAD + metabolism, accompanied by increased expression of CD38, a major NAD + ‐glycohydrolase, in colitis. Restoring NAD + levels through supplementation with its precursors or pharmacological inhibition of CD38 activity effectively alleviated the pathological symptoms of colitis. Mechanistically, colitis induced a pronounced upregulation of CD38 specifically in macrophages. Myeloid‐specific deletion of Cd38 s ignificantly attenuated both metabolic disturbances and inflammatory responses associated with colitis. These findings identify macrophage CD38 as a critical regulator of intestinal inflammation and highlight the CD38/NAD + axis as a potential therapeutic target for IBD. image Key points Altered NAD + metabolism is closely associated with intestinal inflammation, yet the specific cellular mechanisms contributing to this decline remain to be fully elucidated. By supplementing with nicotinamide mononucleotide or inhibiting the enzyme CD38 that consumes NAD + with drugs, the NAD + level can be effectively restored, which can alleviate the colitis induced by dextran sulphate sodium to a certain extent. During intestinal inflammation, the upregulation of CD38 is predominantly driven by infiltrating macrophages. Myeloid‐specific deletion of CD38 preserves NAD + homeostasis and ameliorates colitis, highlighting its essential role in disease progression. Targeting macrophage CD38 establishes a key regulatory link between NAD + metabolism and intestinal inflammation, providing a potential therapeutic strategy for inflammatory bowel diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Animal Nutrition Institute, Sichuan Agricultural University, Chengdu, China.
- Key Laboratory for Animal Disease-Resistant Nutrition of the Ministry of Education of China, Sichuan Agricultural University, Chengdu, China.
- Animal Nutrition and Efficient Feed Utilization Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu, Sichuan, China.
ORCID profiles: Xiaohan Yang, Bin Feng, Lun Hua
Funding
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Cite
APA
Wu, Y., Yang, X., Jin, X., Jiang, X., Jin, C., Feng, B., Che, L., Xu, S., Lin, Y., Wu, Hua, L., & Zhuo, Y. (2026). Macrophage‐derived CD38 mediates colitis through NAD + depletion. The Journal of Physiology. https://doi.org/10.1113/jp291548
Vancouver
Wu Y, Yang X, Jin X, Jiang X, Jin C, Feng B, et al. Macrophage‐derived CD38 mediates colitis through NAD + depletion. The Journal of Physiology. 2026. doi:10.1113/jp291548
BibTeX
@article{Wu2026,
author = {Wu, Yanni and Yang, Xiaohan and Jin, Xianyang and Jiang, Xuemei and Jin, Chao and Feng, Bin and Che, Lianqiang and Xu, Shengyu and Lin, Yan and Wu, De and Hua, Lun and Zhuo, Yong},
title = {Macrophage‐derived CD38 mediates colitis through NAD + depletion},
journal = {The Journal of Physiology},
year = {2026},
doi = {10.1113/jp291548}
}
EUVIMED